Imipenem-cilastatin as initial therapy for febrile cancer patients

G. P. Bodey; M. E. Alvarez; P. G. Jones; K. V. Rolston; L. Steelhammer; V. Fainstein

doi:10.1128/AAC.30.2.211

Imipenem-cilastatin as initial therapy for febrile cancer patients

G. P. Bodey, M. E. Alvarez, P. G. Jones, K. V. Rolston, L. Steelhammer, V. Fainstein

Research output: Contribution to journal › Article › peer-review

51 Scopus citations

Abstract

Imipenem-cilastatin was used to treat 79 febrile episodes in 71 cancer patients, most of whom had neutropenia. The overall response rate was 67%, and 76% of the 45 documented infections responded. The response rates for septicemias and pneumonias were 79 and 62%, respectively. Only 1 of the 17 infections caused by gram-negative bacilli failed to respond to this therapy. The most common side effects were skin rash, nausea, and diarrhea. Eight superinfections were detected during therapy.

Original language	English (US)
Pages (from-to)	211-214
Number of pages	4
Journal	Antimicrobial Agents and Chemotherapy
Volume	30
Issue number	2
DOIs	https://doi.org/10.1128/AAC.30.2.211
State	Published - 1986

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)
Infectious Diseases

Divisions

Infectious Disease

Access to Document

10.1128/AAC.30.2.211

Cite this

@article{2cd1963dbb074631acac0a8b7a13a7fa,

title = "Imipenem-cilastatin as initial therapy for febrile cancer patients",

abstract = "Imipenem-cilastatin was used to treat 79 febrile episodes in 71 cancer patients, most of whom had neutropenia. The overall response rate was 67\%, and 76\% of the 45 documented infections responded. The response rates for septicemias and pneumonias were 79 and 62\%, respectively. Only 1 of the 17 infections caused by gram-negative bacilli failed to respond to this therapy. The most common side effects were skin rash, nausea, and diarrhea. Eight superinfections were detected during therapy.",

author = "Bodey, \{G. P.\} and Alvarez, \{M. E.\} and Jones, \{P. G.\} and Rolston, \{K. V.\} and L. Steelhammer and V. Fainstein",

year = "1986",

doi = "10.1128/AAC.30.2.211",

language = "English (US)",

volume = "30",

pages = "211--214",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "2",

}

TY - JOUR

T1 - Imipenem-cilastatin as initial therapy for febrile cancer patients

AU - Bodey, G. P.

AU - Alvarez, M. E.

AU - Jones, P. G.

AU - Rolston, K. V.

AU - Steelhammer, L.

AU - Fainstein, V.

PY - 1986

Y1 - 1986

N2 - Imipenem-cilastatin was used to treat 79 febrile episodes in 71 cancer patients, most of whom had neutropenia. The overall response rate was 67%, and 76% of the 45 documented infections responded. The response rates for septicemias and pneumonias were 79 and 62%, respectively. Only 1 of the 17 infections caused by gram-negative bacilli failed to respond to this therapy. The most common side effects were skin rash, nausea, and diarrhea. Eight superinfections were detected during therapy.

AB - Imipenem-cilastatin was used to treat 79 febrile episodes in 71 cancer patients, most of whom had neutropenia. The overall response rate was 67%, and 76% of the 45 documented infections responded. The response rates for septicemias and pneumonias were 79 and 62%, respectively. Only 1 of the 17 infections caused by gram-negative bacilli failed to respond to this therapy. The most common side effects were skin rash, nausea, and diarrhea. Eight superinfections were detected during therapy.

UR - https://www.scopus.com/pages/publications/0022479698

UR - https://www.scopus.com/inward/citedby.url?scp=0022479698&partnerID=8YFLogxK

U2 - 10.1128/AAC.30.2.211

DO - 10.1128/AAC.30.2.211

M3 - Article

C2 - 3532942

AN - SCOPUS:0022479698

SN - 0066-4804

VL - 30

SP - 211

EP - 214

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 2

ER -

Imipenem-cilastatin as initial therapy for febrile cancer patients

Abstract

ASJC Scopus subject areas

Divisions

Access to Document

Other files and links

Fingerprint

Cite this